This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Clinical Epigenetics Open Access 07 October 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratner, M. Small biotech steers HDAC inhibitor to clinic. Nat Biotechnol 32, 853–854 (2014). https://doi.org/10.1038/nbt0914-853
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0914-853
This article is cited by
-
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Clinical Epigenetics (2019)
-
FDA approves three different multiple myeloma drugs in one month
Nature Biotechnology (2016)
-
Bioanalytical approaches for the detection of protein acetylation-related enzymes
Analytical and Bioanalytical Chemistry (2016)